Several phase I clinical trials have been sponsored by MD Anderson Cancer for the treatment of patients with advanced non-Hodgkin's lymphoma, ALL, and chronic lymphocytic leukemia by infusion of SB-modified CD19-specific CAR-T cells following hematopoietic stem cell transplantation (HSCT) (NCT00968760, NCT01362452, NCT01497184, NCT01653717, and NCT02529813). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.